Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
35.61
-1.75 (-4.68%)
At close: Apr 1, 2025, 4:00 PM
35.10
-0.51 (-1.43%)
Pre-market: Apr 2, 2025, 4:38 AM EDT

Apogee Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Net Income
-182.15-83.99-43.4
Depreciation & Amortization
0.19--
Loss (Gain) From Sale of Investments
-12.24-3.07-
Stock-Based Compensation
23.336.12.34
Other Operating Activities
1.690.0912.44
Change in Accounts Payable
-1.071.610.46
Change in Other Net Operating Assets
-0.934.4910.25
Operating Cash Flow
-171.17-74.76-17.92
Capital Expenditures
-1.15-0.17-
Investment in Securities
-299.31-273.74-
Investing Cash Flow
-300.46-273.91-
Issuance of Common Stock
495.11315.39-
Other Financing Activities
---0.75
Financing Cash Flow
495.11315.39183.62
Net Cash Flow
23.47-33.28165.7
Free Cash Flow
-172.33-74.93-17.92
Free Cash Flow Per Share
-3.12-3.00-7.28
Levered Free Cash Flow
-113.42-45.5-
Unlevered Free Cash Flow
-113.42-45.5-
Change in Net Working Capital
0.24-6.69-
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q